Harm Reduction 101
Once you register for the course, you will have 30 days from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
Primary care physicians, nurses, mental health professionals, substance use disorder professionals, or any clinic staff who support behavioral health services.
This session will help attendees better understand the complex intersection between pain and opioid use disorder. It will help attendees identify key features of both and identify effective treatments.
Iowa is designated as a Health Professional Shortage Area especially for treatment and management of behavioral health disorders. The Behavioral Health ECHO learning series will utilize the ECHO Model to train and support primary care team members, behavioral health professionals and case managers in treatment and management of substance use disorders, psychiatric illnesses and associated co-morbidities, with the goal to help enhance integrated care in identifying and treating these concerns in their patients. This will be done by disseminating evidence based best practice care to improve patient outcomes in the form of didactic instruction as well as the feedback provided by the hub team experts and peers during case discussions will enhance quality of care and consequently patient health outcomes.
- Summarize the history and principles of harm reduction.
- Identify examples of harm reduction.
- Explain the importance of harm reduction.
- Identify harm reduction efforts happening in Iowa.
- Incorporate harm reduction practices into your work.
Recording date: May 14, 2021
Date of original release: May 20, 2021
Most recent review/update: May 20, 2021
Termination date: May 19, 2024
Systems Integration Coordinator at IDPH Division of Behavioral Health Contracting
Megan Westerly, MSN, BA, RN
Clinical Quality Consultant, Iowa PCA
Sarah Vannice, MSc
Sarah Vannice joined the IDPH Bureau of Substance Abuse in November 2019 as a Community Health Consultant for the State Opioid Response (SOR) and as a Project Coordinator for the Promoting the Integration of Primary and Behavioral Healthcare Grant (PIPBHC).
Sarah holds a Master’s of Science in Epidemiology from the University of Ottawa, Ontario, and a Bachelor of Arts degree in Anthropology from McGill University in Montreal, Quebec. Sarah began her career within academia and spent five years with the HIV and Hepatitis C Prevention Research Team at the University of Iowa. There she wrote grants and coordinated and managed a variety of research projects with and for people who smoke crack and inject drugs.
Seeking more organizational experience, Sarah accepted a position as the Harm Reduction and Health Promotion Project Officer for the Canadian Public Health Association’s Cannabis project. There Sarah helped to facilitate community consultations across Canada on the eve of federal cannabis legalization to determine knowledge needs among providers within Canadian communities. Prior to her position within the Bureau of Substance Abuse, Sarah was a Research and Policy Analyst at the Canadian Center on Substance Use and Addiction, specializing in cannabis and public health.
Sarah is passionate about health equity, healthy communities and coffee. She is the mom of two rambunctious boys, and loves to travel and laugh (which you have probably heard, as it is often and loud). She is originally from Champaign, Illinois, and has enjoyed moving back to the Midwest. She looks forward to learning more about Iowa, the warmer weather, Hinterland and RAGBRAI!
Gagandeep Lamba, MA, MS, MBA
Iowa Primary Care Association
Iowa Primary Care Association
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Iowa Primary Care Association. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other Healthcare Professionals: This live activity is designated for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
No commercial interest company provided financial support for this continuing education activity.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with commercial interest companies to disclose.
- Julie Baker, MPA, CHCEF, Planning Committee Member
- Bery Engebretsen, MD, Planning Committee Member
- Nicolas Foss, MS, IADC, BACC, ICGC-II, Planning Committee Member
- Gagandeep Lamba, MA, MS, MBA, Activity Director/Coordinator, Planning Committee Member, and Moderator
- Elizabeth Noble, Activity Coordinator and Moderator
- Danielle O'Brien-Day, LMHC, CRC, Planning Committee Member
- Nicole Gastala, MD, Planning Committee Member
- Andrea Storjohann, MSN, ARNP, PMHNP-BC, CADC, Planning Committee Member
- Liz Sweet, Speaker
- Sarah Vannice, MSc, Speaker
- Megan Westerly, MSN, BA, RN - Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with commercial interest companies to disclose.
- Janice Landy, MD, Planning Committee Member and Speaker - Does not have a conflict with a commercial interest company; however, does intend to discuss off-label uses of commercial products.
The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2B
- 1.00 CE Contact Hour(s)
- 1.00 IBON